Press | FuturHealth

More from the Newsroom

Press Release FuturHealth to Deliver Affordable, FDA-Approved GLP-1s Nationwide As restrictions tighten on compounded semaglutide, FuturHealth now offers name-brand GLP-1s—like Wegovy®— through Novo's cash-pay program July 30, 2025

Press Release FuturHealth Adds Powerhouse EVP Keith Koch to Lead Growth and Experience Strategy April 15, 2025

Press Release FuturHealth Releases New Efficacy Data Data shows enhanced weight loss outcomes with GLP-1 treatments February 25, 2025

Quick Read FuturHealth Achieves HITRUST i1 Certification HITRUST certification validates that FuturHealth is operating leading security practices to protect sensitive information February 21, 2025

Take precaution with, and read all warnings concerning, GLP-1s, as they may cause serious side effects, including a risk of thyroid c-cell tumors. Do not use if you or your family have a history of a type of thyroid cancer called MTC (medullary thyroid carcinoma) or MEN 2 (multiple endocrine neoplasia syndrome). *Images of the FH application are representative of the types of features and services offered and may not exactly match what is shown in the application. *Individual results may vary based on starting weight and program adherence including but not limited to diet and exercise. Average % body weight reduction as analyzed by InCSD in “A Retrospective Study to Evaluate the Effectiveness of FuturHealth Program Alone or in Combination with GLP-1 Treatment in Weight Management in Participants ≥ 18 Years Old.” Contact us